Inventor · disambiguated record
Pui Yee Ng
Also filed as: NG PUI YEE
79 granted patents·12 pending applications·1,088 citations·filing 2006–2025
99Inventor score
Files withFORMA THERAPEUTICS INC38VALO HEALTH INC17VALO EARLY DISCOVERY INC11SIRTRIS PHARMACEUTICALS INC7GLAXOSMITHKLINE LLC5
Top patents by PatentIndex Score
91 records- 0199US10829461B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 10, 2020·15 cites·12 claims
- 0299US10829462B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 10, 2020·15 cites·17 claims
- 0399US10377726B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·22 cites·10 claims
- 0499US10112915B23-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Oct 30, 2018·41 cites·31 claims
- 0598US11279681B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Mar 22, 2022·6 cites·20 claims
- 0698US10822316B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 3, 2020·10 cites·15 claims
- 0798US10494354B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·17 cites·17 claims
- 0898US10494353B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·17 cites·12 claims
- 0998US10472337B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 12, 2019·17 cites·12 claims
- 1098US10428031B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 1, 2019·15 cites·20 claims
- 1198US10421731B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 24, 2019·15 cites·19 claims
- 1298US10421732B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 24, 2019·16 cites·13 claims
- 1398US10414738B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·16 cites·20 claims
- 1498US10239845B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Mar 26, 2019·25 cites·42 claims
- 1598US10214501B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Feb 26, 2019·20 cites·38 claims
- 1698US10214500B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Feb 26, 2019·20 cites·35 claims
- 1798US9630922B23-spiro-7-hydroxamic acid tetralins as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Apr 25, 2017·49 cites·33 claims
- 1898US7345178B2Sirtuin modulating compoundsSIRTRIS PHARMACEUTICALS INC·Filed 2006·Granted Mar 18, 2008·158 cites·30 claims
- 1997US11702412B2Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Jul 18, 2023·4 cites·18 claims
- 2097US10988450B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Apr 27, 2021·6 cites·14 claims
- 2197US10513501B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 24, 2019·11 cites·20 claims
- 2297US10494352B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·12 cites·20 claims
- 2397US10494351B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·12 cites·20 claims
- 2497US10464910B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 5, 2019·12 cites·15 claims
- 2597US10464909B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 5, 2019·12 cites·17 claims
- 2697US10457652B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 29, 2019·12 cites·18 claims
- 2797US10450283B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 22, 2019·14 cites·16 claims
- 2897US10450284B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 22, 2019·14 cites·13 claims
- 2997US10442776B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 15, 2019·15 cites·18 claims
- 3097US10183934B2Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Jan 22, 2019·27 cites·28 claims
- 3197US9637453B23-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted May 2, 2017·51 cites·31 claims
- 3297US7829556B2Sirtuin modulating compoundsSIRTRIS PHARMACEUTICALS INC·Filed 2008·Granted Nov 9, 2010·115 cites·12 claims
- 3396US12213969B22-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitorsVALO HEALTH INC·Filed 2023·Granted Feb 4, 2025·2 cites·20 claims
- 3496US11730721B22-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Aug 22, 2023·3 cites·20 claims
- 3596US10407418B2Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 10, 2019·16 cites·19 claims
- 3696US8093401B2Sirtuin modulating compoundsNUNES JOSEPH J·Filed 2006·Granted Jan 10, 2012·32 cites·8 claims
- 3796US8088928B2Sirtuin modulating compoundsNUNES JOSEPH J·Filed 2006·Granted Jan 3, 2012·32 cites·13 claims
- 3895US8044198B2Sirtuin modulating compoundsSIRTRIS PHARMACEUTICALS INC·Filed 2008·Granted Oct 25, 2011·29 cites·10 claims
- 3995US7893086B2Sirtuin modulating compoundsSIRTRIS PHARMACEUTICALS INC·Filed 2008·Granted Feb 22, 2011·34 cites·23 claims
- 4094US10479772B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 19, 2019·6 cites·13 claims
- 4194US7855289B2Sirtuin modulating compoundsSIRTRIS PHARMACEUTICALS INC·Filed 2006·Granted Dec 21, 2010·34 cites·23 claims
- 4293US10874649B22-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Dec 29, 2020·9 cites·15 claims
- 4393US10870645B2Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Dec 22, 2020·9 cites·17 claims
- 4493US10555935B22-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2017·Granted Feb 11, 2020·11 cites·17 claims
- 4593US9745253B2Alpha-cinnamide compounds and compositions as HDAC8 inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Aug 29, 2017·10 cites·53 claims
- 4692US11891365B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2021·Granted Feb 6, 2024·1 cites·23 claims
- 4789US11274084B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Mar 15, 2022·1 cites·18 claims
- 4889US10538496B2Methods using HDAC11 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Jan 21, 2020·3 cites·5 claims
- 4989US10508088B2Methods using HDAC11 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 17, 2019·3 cites·11 claims
- 5088US10266487B2Alpha-cinnamide compounds and compositions as HDAC8 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Apr 23, 2019·4 cites·16 claims
Showing the top 50 of 91 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →